ID: ALA5208275

Max Phase: Preclinical

Molecular Formula: C45H53ClFN7O10

Molecular Weight: 906.41

Associated Items:

Representations

Canonical SMILES:  O=C(CCC(=O)N1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1)NCCOCCOCCOCCNC(=O)COc1ccc2c(c1)CCCN2C(=O)CCl

Standard InChI:  InChI=1S/C45H53ClFN7O10/c46-29-43(58)54-15-3-4-32-28-33(8-10-39(32)54)64-30-41(56)49-14-21-62-23-25-63-24-22-61-20-13-48-40(55)11-12-42(57)52-16-18-53(19-17-52)45(60)36-26-31(7-9-37(36)47)27-38-34-5-1-2-6-35(34)44(59)51-50-38/h1-2,5-10,26,28H,3-4,11-25,27,29-30H2,(H,48,55)(H,49,56)(H,51,59)

Standard InChI Key:  WWQBPDINBLGBQK-UHFFFAOYSA-N

Associated Targets(Human)

MDA-MB-436 532 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CAPAN-1 772 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-468 9477 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 906.41Molecular Weight (Monoisotopic): 905.3526AlogP: 2.60#Rotatable Bonds: 22
Polar Surface Area: 201.80Molecular Species: NEUTRALHBA: 11HBD: 3
#RO5 Violations: 2HBA (Lipinski): 17HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 9.96CX Basic pKa: CX LogP: 0.95CX LogD: 0.95
Aromatic Rings: 4Heavy Atoms: 64QED Weighted: 0.08Np Likeness Score: -1.41

References

1. Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R..  (2022)  Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.,  236  [PMID:35430559] [10.1016/j.ejmech.2022.114321]

Source